Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TACR3 | P29371 | 8/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.34 |
| ▸ | ACACB | O00763 | 2/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.33 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3283641 | 0.83 | CTSB (0.44) | CTSBKDM4ESMN1; SMN2ALDH1A1TACR3 | |
| SCHEMBL3040552 | 0.78 | CTSB (0.43) | CTSBKDM4ESMN1; SMN2ALDH1A1TACR3 | |
| SCHEMBL3277219 | 0.78 | CTSB (0.42) | CTSBKDM4ESMN1; SMN2ALDH1A1TACR3 | |
| SCHEMBL3276524 | 0.77 | CTSB (0.42) | CTSBKDM4ESMN1; SMN2ALDH1A1TACR3 | |
| SCHEMBL5152264 | 0.77 | ADRB3 (0.44) | CTSB | |
| SCHEMBL14623167 | 0.76 | CTSB (0.38) | CTSBKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL1013638 | 0.74 | KDM4E (0.49) | CTSBKDM4ESMN1; SMN2ALDH1A1TACR3 | |
| SCHEMBL1013614 | 0.74 | KDM4E (0.49) | CTSBKDM4ESMN1; SMN2ALDH1A1TACR3 | |
| SCHEMBL1069117 | 0.74 | KDM4E (0.49) | CTSBKDM4ESMN1; SMN2ALDH1A1TACR3 | |
| SCHEMBL1941411 | 0.74 | ADRB3 (0.47) | CTSBKDM4ESMN1; SMN2ALDH1A1TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1455809-B1 | INHIBITORS OF HEPATITIS C VIRUS | BRISTOL MYERS SQUIBB CO (US) | 2011-06-15 | — | — | EP | disclosed |
| US-6867185-B2 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-03-15 | — | — | US | disclosed |
| US-20040038872-A1 | Inhibitors of hepatitis C virus | BRISTOL-MYERS SQUIBB COMPANY | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040038872-A1 | Inhibitors of hepatitis C virus | HAVCR2, LIPC, ZC3HAV1 | CTSB 138/4885KDM4E 3631/4885SMN1; SMN2 4699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.